For patients starting GLP-1 therapy, food tolerance becomes deeply personal
Unlike fad diets, our medically supervised approach addresses the biological factors that make weight loss difficult, helping you achieve and maintain your ideal weight
Semaglutide is not recommended for those who are pregnant, breastfeeding, have a history of medullary thyroid cancer, pancreatitis, gallbladder disease, or a diagnosis of multiple endocrine neoplasia syndrome type 2
21st ed
They may directly switch to Wegovy and increase the dosage afterwards
Undeniably powerful weight loss in a pen and a pill 1-3 Along with diet and exercise Wegovy HD In adults with obesity, Efficacy estimand: ~21% (20.7%) mean weight loss with Wegovy HD (semaglutide) injection 7.2 mg vs 2.4% with placebo at 72 weeks, in an idealized scenario estimating efficacy if all patients remained on treatment and used no other weight-loss therapies* Treatment regimen estimand: ~19% (18.8%) mean weight loss with Wegovy HD vs 3.9% with placebo at 72 weeks, for all patients in the trial regardless of whether patients stayed on treatment or took other weight-loss therapies For adults taking Wegovy for weight reduction: Those who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly